Sg3 Management, LLC Intra Cellular Therapies, Inc. Call Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $143,338 - $229,733	-3,700 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $37,336 - $55,237	-1,300 Reduced 26.0%	3,700 $138,000
Q2 2021 Aug 16, 2021	BUY	$29.3 - $44.5 $146,500 - $222,500	5,000 New	5,000 $204,000
Q1 2021 May 17, 2021	SELL	$30.8 - $39.51 $354,200 - $454,365	-11,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $268,410 - $370,530	11,500 New	11,500 $366,000
Q3 2020 Nov 13, 2020	SELL	$17.61 - $31.86 $352,200 - $637,200	-20,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$14.35 - $26.64 $287,000 - $532,800	20,000 New	20,000 $513,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.17B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.